No Photo Available

Last Update

2016-11-15T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Scott Siegel?

Dr. Scott A. Siegel Ph.D.

Managing Director

Milestone Life Sciences

Direct Phone: (908) ***-****       

Email: s***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Milestone Life Sciences

Background Information

Employment History

Chief Operating Officer and Vice President, Business Development

Ezose Sciences Inc

Lecturer- MBA Communications Program (Part Time)

The Wharton School

Vice President, Corporate Development

Redpoint Bio Corporation

Position, New Business Development

Johnson & Johnson

Senior Director, Preclinical Research and Development

start-up Phytera , Inc.

Adjunct Associate Professor of Microbiology

University of Pennsylvania

Affiliations

Member of Advisory Board
IIR Ltd

Education

Yale University School of Medicine

Bachelor of Science degree

biology

State University of New York , College at New Paltz

MBA

communications

Wharton School

Ph.D.

Biochemistry

SUNY

Ph.D.

Biochemistry

SUNY Downstate Medical Center

Ph.D.

biochemistry

SUNY Downstate Medical

Ph.D.

biochemistry

State University of New York

Web References (76 Total References)


Scott Siegel, PhD, ...

ilsebio.com [cached]

Scott Siegel, PhD, Managing Director, Milestone Life Sciences, LLC


SCOTT A. SIEGEL, ...

ilsebio.com [cached]

SCOTT A. SIEGEL, PHD

...
SCOTT A. SIEGEL, PHD VP BUSINESS DEVELOPMENT
Dr. Scott Siegel brings over 25 years of experience in the biotechnology and pharmaceutical industries and academia to his role at ILSE. He founded Milestone Life Sciences, a consultancy to biotech and pharma companies in strategy, business development and transactions, and currently also serves as a Lecturer in the MBA communications program at the Wharton School. Dr. Siegel was previously COO and VP, Business Development for Ezose Sciences, a Japan-owned "omics" start-up where he built and then led operations, completing transactions across 3 continents. Prior to that he was VP, Corporate Development for Redpoint Bio, a microcap public biotech with unique technology in taste science and diabetes. Dr. Siegel previously spent eight years with Johnson & Johnson in New Business Development and WW Strategic Marketing. His responsibilities spanned scientific and commercial scouting, assessment and alliances across a breadth of technology and product in-licensing opportunities. Prior to J&J he served in various R&D roles including Senior Director, Preclinical R&D for the start-up Phytera, Inc., Associate Director, Immunobiology for Centocor, Inc. and Section Leader, Immunodiagnostics for Becton Dickinson and Co. Dr. Siegel previously also served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania and Executive-in-Residence for the NYU Office of Industrial Liaison and Tech. Transfer.
Dr. Siegel earned his Ph.D. in Biochemistry from SUNY, Downstate Medical Center and completed postdoctoral studies in Pharmacology at the Yale University School of Medicine. He has over 60 publications and patents and has contributed to the development of 3 launched products, including co-inventor of Remicade®, a blockbuster anti-TNF therapy that to-date has been used to treat over 2 million patients with autoimmune disorders.


Scott A. Siegel, ...

www.ilsebio.com [cached]

Scott A. Siegel, PhD VP Business Development

...
Dr. Scott Siegel brings over 25 years of experience in the biotechnology and pharmaceutical industries and academia to his role at ILSE. He founded Milestone Life Sciences, a consultancy to biotech and pharma companies in strategy, business development and transactions, and currently also serves as a Lecturer in the MBA communications program at the Wharton School. Dr. Siegel was previously COO and VP, Business Development for Ezose Sciences, a Japan-owned "omics" start-up where he built and then led operations, completing transactions across 3 continents. Prior to that he was VP, Corporate Development for Redpoint Bio, a microcap public biotech with unique technology in taste science and diabetes. Dr. Siegel previously spent eight years with Johnson & Johnson in New Business Development and WW Strategic Marketing. His responsibilities spanned scientific and commercial scouting, assessment and alliances across a breadth of technology and product in-licensing opportunities. Prior to J&J he served in various R&D roles including Senior Director, Preclinical R&D for the start-up Phytera, Inc., Associate Director, Immunobiology for Centocor, Inc. and Section Leader, Immunodiagnostics for Becton Dickinson and Co. Dr. Siegel previously also served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania and Executive-in-Residence for the NYU Office of Industrial Liaison and Tech. Transfer.
Dr. Siegel earned his Ph.D. in Biochemistry from SUNY, Downstate Medical Center and completed postdoctoral studies in Pharmacology at the Yale University School of Medicine. He has over 60 publications and patents and has contributed to the development of 3 launched products, including co-inventor of Remicade®, a blockbuster anti-TNF therapy that to-date has been used to treat over 2 million patients with autoimmune disorders.


Scott ...

ilsebio.com [cached]

Scott Siegel

...
SCOTT A. SIEGEL, PHD


Scott Siegel, PhD, Vice ...

ilsebio.com [cached]

Scott Siegel, PhD, Vice President of Business Development for Institute for Life Science Entrepreneurship (ILSE) addressed attendees of the organization's second stakeholder forum. Siegel explained how the organization planned to build on early successes and further contribute to the area's life sciences industry and ILSE's mission to accelerate life sciences innovation in medicine, devices and other technologies to improve human health.

...
For information, contact Scott Siegel, PhD, at (908) 737-1922 x104 or ssiegel@ilsebio.com. Visit ILSE online at www.ilsebio.com.
Photos taken during ILSE 2nd Stakeholder Forum, March 8, 2016:
GroupPhoto-Richardson-Siegel-Bostian-Cypess-Connelly
Pictured from left: Dr. Thomas Richardson, VP, Strategic Initiatives, BioNJ; Dr. Scott Siegel, Business Development, ILSE; Dr. Keith Bostian, Interim CEO, ILSE, and Dean, New Jersey Center for Science, Technology & Mathematics (NJCSTM) and Office of Technology Transfer; Dr. Raymond Cypess, CEO, ATCC; Phillip Connelly, EVP, Kean University.

Similar Profiles

Other People with this Name

Other people with the name Siegel

Sarah Siegel
NASDAQ

Alexandra Siegel
Irell & Manella LLP

Annie Siegel
Roth Capital Partners , LLC

Mark Siegel
Tesla Motors Inc

Beth Siegel
ARAMARK Corporation

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory